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1. Introduction
Aging effects the physiology of every cell of the human 
body leading to changes and/or loss of function. The 
brain is particularly susceptible to deterioration and 
neurodegeneration; the progressive loss of structure or 
function of neurones, can be found to varying degrees 
in the brains of all age groups (Wyss-Coray, 2016). Such 
changes are irreversible, non-curative, contribute to age-
related declines in cognitive function and memory and are 
a major risk factor for neurological disorders, including 
Parkinson’s and Alzheimer’s disease (Wahl et al., 2017; 
Wyss-Coray, 2016). As the age of the population increases, 
so does the socio-economic burden of neurodegeneration 
thus highlighting the need to identify neuroprotective 
agents (Gillette-Guyonnet et al., 2013; Lalkovičová and 
Danielisová, 2016; Wahl et al., 2017; Wyss-Coray, 2016).
The mechanisms driving neurodegeneration are 
complicated and not fully understood although it is 
widely accepted that disturbances in hormonal balance, 
inflammation, metabolism and oxidative stress contribute. 
The relationship between the gut microbiota and the brain 
(the gut-brain-axis) and neurodegeneration is related 
to changes/imbalances in the composition of the gut 
microbiota causing decreases in population diversity and 
functionality (Dinan and Cryan, 2017). The gut-brain axis is 
a dynamic bi-directional system consisting of neurological, 
endocrine and immunological elements. If the microbial 
balance of the gut is disrupted, communication with the 
brain is disturbed and this has been associated with low 
grade inflammation, increased oxidative status, unbalanced 
energy homeostasis and increased cellular degeneration 
(Westfall et al., 2017). Alterations of the gut microbiota 
composition can affect many brain biological processes (e.g. 
development and neurogenesis) and behavioural traits (e.g. 
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Abstract
Neurodegeneration has been linked to changes in the gut microbiota and this study compares the neuroprotective 
capability of two bacterial consortia, known as Lab4 and Lab4b, using the established SH-SY5Y neuronal cell model. 
Firstly, varying total antioxidant capacities (TAC) were identified in the intact cells from each consortia and their 
secreted metabolites, referred to as conditioned media (CM). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and Crystal Violet (CV) assays of cell viability revealed that Lab4 CM and Lab4b CM could induce 
similar levels of proliferation in SH-SY5Y cells and, despite divergent TAC, possessed a comparable ability to protect 
undifferentiated and retinoic acid-differentiated cells from the cytotoxic actions of rotenone and undifferentiated 
cells from the cytotoxic actions of 1-methyl-4-phenylpyridinium iodide (MPP+). Lab4 CM and Lab4b CM also 
had the ability to attenuate rotenone-induced apoptosis and necrosis with Lab4b inducing the greater effect. Both 
consortia showed an analogous ability to attenuate intracellular reactive oxygen species accumulation in SH-SY5Y 
cells although the differential upregulation of genes encoding glutathione reductase and superoxide dismutase by 
Lab4 CM and Lab4b CM, respectively, implicates the involvement of consortia-specific antioxidative mechanisms 
of action. This study implicates Lab4 and Lab4b as potential neuroprotective agents and justifies their inclusion in 
further in vivo studies.
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anxiety, depression, learning and memory). Probiotics are 
defined as ‘live microorganisms which when administered 
in adequate amounts confer a health benefit on the host’ 
(FAO/WHO, 2006) and have been demonstrated to play 
a role in maintaining microbial homeostasis within the 
gut (Kumar et al., 2016; Umbrello and Esposito, 2016). 
Indeed, probiotic organisms have shown beneficial effects 
on neurodegenerative disorders (Akbari et al., 2016; Bonfili 
et al., 2017, 2018; Kobayashi et al., 2017; Nimgampalle 
and Kuna, 2017) and animal studies with probiotics have 
shown clear neuroprotective effects (Ait-Belgnaoui et al., 
2014; Distrutti et al., 2014; Möhle et al., 2016; Park et al., 
2017). The aetiology of neurodegeneration is complex 
and the functional diversity of probiotics may facilitate 
the simultaneous targeting of multiple disease-related 
mechanisms (Elufioye et al., 2017; Faden and Stoica, 2007). 
Of particular interest are the antioxidant properties of such 
bacteria (Mishra et al., 2015; Wang et al., 2017) that can 
target the susceptibility of neurones to oxidative damage, 
a key driver of neurodegeneration (Liu et al., 2017).
The Lab4 and Lab4b probiotic consortia comprise distinct 
populations of Bifidobacterium spp. and Lactobacillus spp. 
Supplementation with Lab4b has been shown to reduce 
the incidence of allergy in infants (Allen et al., 2010, 2014) 
whilst Lab4 impacted on both inflammation (Davies et 
al., 2018; Garaiova et al., 2015; Hepburn et al., 2013) and 
metabolism (Michael et al., 2016, 2017). Some probiotic 
bacteria are known producers of metabolites with neuro-
modulatory capability (Sarkar et al., 2016) and Lab4 has 
been shown to improve memory and alter brain metabolite 
profiles in aging rats (O’Hagan et al., 2017). The aim of this 
in vitro study was to compare the neuroprotective potential 
of two distinct microbial populations (Lab4 and Lab4b) by 
assessing their ability to protect SH-SY5Y neuronal cells 
against oxidative stress and investigate the potential modes 
of action of the two different consortia.
2. Methods and reagents
Materials and reagents
All materials and reagents were purchased from Sigma-
Aldrich (Poole, UK) unless otherwise stated.
Preparation of bacterial cultures
DeMan Rogosa Sharpe (MRS) broth (10 ml) was inoculated 
with freeze dried powder (10 mg) of Lab4 (composed of 
Lactobacillus acidophilus CUL21 (NCIMB 30156), L. 
acidophilus CUL60 (NCIMB 30157), Bifidobacterium 
bifidum CUL20 (NCIMB 30153) and Bifidobacterium 
animalis subsp. lactis CUL34 (NCIMB 30172)) or Lab4b 
(composed of Lactobacillus salivarius CUL61 (NCIMB 
30211), Lactobacillus paracasei CUL08 (NCIMB 30154), 
Bifidobacterium bifidum CUL20 (NCIMB 30153), B. 
animalis subsp. lactis CUL34 (NCIMB 30172)) and 
incubated anaerobically (10% carbon dioxide, 10% hydrogen 
and 80% nitrogen) without shaking at 37 °C for 18 h.
Preparation of Lab4 and Lab4b conditioned media
Bacteria were harvested from 18 h cultures by centrifugation 
(2,500×g for 20 min), suspended in phosphate buffered 
saline (PBS), and centrifuged (2,500×g for 20 min). The 
resulting bacterial pellet was adjusted to a concentration 
of 1×109 cfu/ml in a 1:1 mix of Dulbecco’s Modified 
Eagle’s medium and Ham F-12 medium (DMEM/F12) 
and incubated under anaerobic conditions at 37 °C for 5 
h, centrifuged (2,500×g for 20 min) and the supernatant 
passed through a 0.22 µm filter (Gilson, Bedfordshire, 
UK) to produce the conditioned media (CM) preparation. 
The CM were adjusted to pH 7.4 using 1 M NaOH and 
supplemented with 100 U/ml penicillin and 100 U/ml 
streptomycin (Labtech, Heathfield, UK). Enumeration at 
the start and end of the 5 h incubation period confirmed 
that no change in bacterial number occurred during this 
period (data not shown). DMEM/F12 supplemented with 
100 U/ml penicillin and 100 U/ml streptomycin was used as 
a diluent for the preparation of CM doses and as a control 
for CM.
Total antioxidant capacity
The total antioxidant capacity (TAC) of intact cells and 
CM was determined using the Total Antioxidant Capacity 
Assay Kit (Abcam, Cambridge, UK) in accordance with 
the manufacturer’s instructions. Prior to measurement, 
intact cells were washed twice in phosphate buffered saline 
(PBS) to remove all traces of culture media and the TAC 
value for PBS subtracted from experimental values. The 
TAC of serum-free DMEM/F12 was subtracted from CM 
values. Data are presented as the mean Trolox equivalent 
antioxidant capacity (mM).
SH-SY5Y cell culture, differentiation and stimulation
SH-SY5Y cells were maintained in DMEM/F12 (Labtech) 
supplemented with 10% (v/v) heat inactivated foetal bovine 
serum (Labtech), penicillin (100 U/ml) and streptomycin 
(100 U/ml) at 37  °C in 5% CO2 and 95% humidity. 
Approximately 24 h before experimentation, cells of ~80% 
confluency were seeded at 5×105 cells/cm2 into appropriate 
tissue culture plates (Costar, Cambridge, UK). Cells 
between passage 21 and 30 were used in this study. Where 
differentiation was required, SH-SY5Y were incubated with 
DMEM/F12 supplemented with 1% (v/v) heat inactivated 
foetal bovine serum, penicillin (100 U/ml), streptomycin 
(100 U/ml) and 10 µM all-trans retinoic acid (ATRA) for 5 
days. Differentiating cells were incubated under light-free 
conditions and the media changed every 2 days. Rotenone 
was dissolved in dimethyl sulfoxide (DMSO) and applied 
Please cite this article as 'in press'  Beneficial Microbes 
 
${
pro
toc
ol}
://w
ww
.w
ag
en
ing
en
ac
ad
em
ic.
co
m/
do
i/p
df/
10
.39
20
/B
M
20
18
.01
05
 - T
ue
sd
ay
, M
arc
h 1
9, 
20
19
 2:
35
:06
 A
M
 - C
ard
iff
 U
niv
ers
ity
 IP
 A
dd
res
s:1
31
.25
1.2
54
.66
 
 In vitro neuroprotective effects of probiotic consortia
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to SH-SY5Y cells at a concentration of 250 nM for viability 
and apoptosis/necrosis assays (Supplementary Figure 
S1A) or 10 µM for intracellular reactive oxygen species 
(ROS) assays (Supplementary Figure S1B). DMSO was also 
included at the relevant concentration in the controls for 
these experiments and is referred to as the vehicle control. 
1-Methyl-4-phenylpyridinium iodide (MPP+) was dissolved 
in water that was included at the relevant concentration 
in the controls for these experiments and is referred to as 
the vehicle control.
MTT-assay
Following exposure to experimental conditions, SH-SY5Y 
cells were washed with 200 µl of warm PBS (pH 7.4) before 
incubation with 100 µl of 3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) solution (500 µg/ml in 
DMEM/F12) for 2 h in 5% CO2 and 95% humidity. The cells 
were then washed in 200 µl of PBS (pH 7.4, 37 °C) before 
the addition of 100 µl of DMSO. The absorbance at 570 
nm was read using a colorimetric spectrophotometer and 
viability was expressed as percentage survival compared to 
untreated cells or cells treated with the appropriate vehicle 
that have been arbitrarily assigned as 100%.
Crystal violet assay
Following exposure to experimental conditions, SH-SY5Y 
cells were washed with 200 µl of PBS (pH 7.4, 37 °C) before 
incubation with 0.2% (w/v) crystal violet solution (in 10% 
(v/v) ethanol) for 5 min at room temperature. The cells 
were then washed three times in PBS (pH 7.4, 37 °C) and 
left to dry at room temperature overnight before 150 µl 
of 10% acetic acid solution (v/v) was added to each well 
and the absorbance read at 595 nm using a colorimetric 
spectrophotometer. Viability is expressed as percentage 
survival compared to untreated cells or cells treated with 
the appropriate vehicle that have been arbitrarily assigned 
as 100%.
Apoptosis and necrosis assay
Levels of apoptosis and necrosis were measured in SH-
SY5Y cells exposed to experimental conditions using the 
RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay 
(Promega, Madison, WI, USA) in accordance with the 
manufacturer’s instructions.
Intracellular reactive oxygen species assay
Intracellular ROS levels were measured in SH-SY5Y cells 
exposed to experimental conditions using the DCFDA 
Cellular ROS Detection Assay Kit (Abcam) in accordance 
with the manufacturer’s instructions. SH-SY5Y cells were 
cultured in phenol red-free DMEM/F12 (Gibco, Paisley, UK) 
to eliminate assay interference by phenol red. Intracellular 
ROS is expressed as a percentage compared to cells treated 
with the appropriate vehicle that have been arbitrarily 
assigned as 100%.
RT-qPCR
Total RNA was isolated using Ribozol (Amresco LLC, Solon, 
OH, USA) and cDNA generated using the High Capacity 
cDNA Reverse Transcription Kit (Life Technologies, Paisley, 
UK) in accordance to the manufacturer’s instructions. 
Real-time qPCR amplification was performed as previously 
described (Michael et al., 2016) using the oligonucleotide 
primers shown in Supplementary Table S1. Ratios of gene 
expression compared to untreated cells were determined 
using 2-(ΔCt1 – ΔCt2), where ΔCt represents the difference 
between the threshold cycle (CT) for each target gene and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 
β-actin mRNA transcript levels.
Statistical analysis
All data are presented as the mean ± standard error of 
the mean (SEM) of the assigned number of independent 
experiments. The normality of all data was assessed using 
histograms and Q-Q plots and data transformations were 
applied where appropriate. For single comparisons, values 
of P were determined using a Student’s t-test. For multiple 
comparisons, P-values were determined using one-way 
analysis of variance (ANOVA) with Tukey’s or Dunnett’s 
T3 post-hoc analysis or, where the data was not normally 
distributed, Kruskal-Wallis ANOVA with Dunns post-hoc 
analysis. All statistical tests were performed using SPSS 
statistical software package version 22 (IBM, Armonk, NY, 
USA). Differences were considered significant when P<0.05.
3. Results
Lab4 and Lab4b consortia possess antioxidant capacity
Antioxidant activity was observed in three independent 
cultures of whole cells of the Lab4 and Lab4b consortia 
(0.105±0.010 and 0.233±0.023 mM, respectively) and 
CM preparations (0.735±0.052 and 0.084±0.057 mM, 
respectively). Significant differences were observed in whole 
cell preparations of Lab4 compared to Lab4b (P=0.042) and 
in CM from Lab4 compared to Lab4b (P=0.026).
Lab4 CM and Lab4b CM can impact upon the viability of 
undifferentiated SH-SY5Y cells
Undifferentiated SH-SY5Y cells were exposed to various 
doses of Lab4 and Lab4b CM for 48 h and viability was 
assessed using the MTT assay (Figure 1A). There was a trend 
of improved viability at all doses that reached significance 
for the 10% Lab4 CM dose (14.8%, P=0.031) compared to 
the control. Similar results were obtained using the CV 
 Please cite this article as 'in press'
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assay (Figure 1B) where significant improvements were 
observed for 25% (17.4%, P=0.018), 10% (23.1%, P<0.001) 
and 5% (16.6%, P=0.031) CM from Lab4 and 50% (20.5%, 
P=0.002), 25% (21.4%, P=0.001) and 10% (16.4%, P=0.034) 
CM from Lab4b compared to the control. No statistically 
significant differences were observed between doses or 
between Lab4 and Lab4b in either assay.
Lab4 CM and Lab4b CM protect undifferentiated SH-SY5Y 
cells against rotenone-induced loss of viability
The toxicity of doses of rotenone in undifferentiated SH-
SY5Y cells was measured (Supplementary Figure S1A). 
Survival rates in SH-SY5Y cells exposed to 250 nM rotenone 
were 53.4% (P<0.001) of the control (Figure 2A) and 
survival rates in the presence of rotenone were improved 
up to 72.1% (P=0.006) and 67.0% (P=0.130) with Lab4 and 
Lab4b CM, respectively (see Supplementary Figure S2 for 
optimisation experiments). This neuroprotective capability 
was confirmed in CV assays (Figure 2B) where the survival 
rate of 75.9% (P<0.001) in rotenone exposed cells increased 
to 91.9% (P=0.062) in the presence of Lab4 CM and 96.9% 
(P=0.007) in the presence of Lab4b CM. No statistically 
significant differences were observed between Lab4 and 
Lab4b in these experiments.
Pre-incubation with Lab4 CM or Lab4b CM protects 
undifferentiated SH-SY5Y cells against rotenone-induced 
loss of viability
Undifferentiated SH-SY5Y cells were incubated with Lab4 
or Lab4b (50% CM) for 2 h prior to the exposure of the 
neuronal cells to 250 nM rotenone. A survival rate of 70.9% 
(P<0.001) was observed in cells treated with rotenone 
and this increased to 86.7% (P=0.053) in Lab4 and 90.3% 
(P=0.033) in Lab4b pre-treated cells (Figure 2C). These 
findings were corroborated using CV assays (Figure 2D) 
where the neuronal survival rate increased from 56.2% 
(P<0.001) in rotenone-treated cells to 69.4% (P=0.035) and 
62.5% (P=0.523) in the Lab4 and Lab4b pre-treated cells, 
respectively. No statistically significant differences were 
observed between Lab4 and Lab4b in these experiments.
Protection of ATRA-differentiated SH-SY5Y cells against 
rotenone-induced loss of viability
SH-SY5Y cell were incubated with 10 µM ATRA for 5 days 
to induce differentiation as described elsewhere (Kovalevich 
and Langford, 2013) and changes to cell morphology and 
gene expression levels of tropomyosin receptor kinase 
B (Kaplan et al., 1993) confirmed the responsiveness of 
SH-SY5Y cells to these conditions (Supplementary Figure 
S4). In ATRA-treated SH-SY5Y cells (Figure 2E), 84.8% 
(P<0.001) of cells remained viable after rotenone exposure 
compared to the control and the survival rate increased 
to 104.9% (P<0.001) and 98.5% (P=0.029) as a result of 
co-incubation with Lab4 and Lab4b CM respectively. 
Pre-incubation for 2 h with Lab4 and Lab4b CM prior to 
rotenone challenge (Figure 2F) significantly improved the 
survival rate from 86.2% (P<0.001) in rotenone-treated cells 
to 109.3% (P<0.001) and 107.2% (P<0.001), respectively. 
These improvements in survival rate were also significantly 
different compared to the control (P<0.001 and P=0.013 
respectively). No statistically significant differences were 
observed between Lab4 and Lab4b in these experiments.
Lab4 CM and Lab4b CM protect undifferentiated SH-SY5Y 
cells against MPP+ induced loss of viability
The toxicity of doses of MPP+ in undifferentiated SH-
SY5Y cells was measured (Supplementary Figure S3) 
and exposure to 2 μM MPP+ reduced viability to 62.4% 
(P<0.001) of the control in these cells (Figure 3A). In the 
presence of CM from Lab4 and Lab4 there was indication 
of improved survival rates at all concentrations tested 
compared to rotenone-treated cells although statistical 
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Figure 1. The effect of Lab4 and Lab4b CM on the viability of undifferentiated SH-SY5Y cells. The viability of undifferentiated SH-
SY5Y cells that were treated with either serum-free DMEM/F12 (untreated control, UC) or treated with various doses of Lab4 or 
Lab4b CM for 48 h was assessed by (A) MTT assay or (B) Crystal Violet assay. Data are expressed as a percentage of the control 
that has been arbitrarily assigned as 100%. The data are presented as the mean ± standard error of the mean of four independent 
experiments. * P<0.05, ** P<0.01, *** P<0.001 or as stated vs untreated cells.
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significance was not achieved. In CV assays, exposure to 
2 μM MPP+ reduced viability to 82.6% (P<0.001) of the 
control (Figure 3B) and indication of improved survival 
was observed upon the addition of Lab4 and Lab4b at 
all concentrations tested that, in the case of 25 and 50% 
CM from Lab4b, were significantly improved to 108.2% 
(P=0.033) and 99.9% (P=0.010), respectively. No statistically 
significant differences were observed between Lab4 and 
Lab4b in these experiments.
Lab4 and Lab4b CM protect undifferentiated SH-SY5Y 
cells against rotenone-induced apoptosis and necrosis
Exposure of undifferentiated SH-SY5Y cells to 250 nM 
rotenone for 24 h resulted in a significant 1.74-fold (P<0.001) 
increase in apoptosis compared to the untreated control 
(Figure 4A) and in the presence of Lab4 and Lab4b CM, 
reduced apoptotic activity was observed (1.54-fold, P=0.040 
and 1.18-fold, P<0.001 respectively). After 48 h exposure 
(Figure 4B), the levels of apoptosis were lower but similar 
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Figure 2. The effect of Lab4 and Lab4b CM on rotenone-induced toxicity in undifferentiated and ATRA-differentiated SH-SY5Y cells. 
The viability of undifferentiated SH-SY5Y cells that were treated with the vehicle control (DMSO) or 250 nM rotenone or 250 nM 
rotenone with Lab4 or Lab4b CM for 24 h was assessed by (A) MTT assay or (B) Crystal Violet assay. The viability of undifferentiated 
SH-SY5Y cells that were pre-incubated with serum-free DMEM/F12 or CM from Lab4 or Lab4b for 2 h prior to the addition of the 
vehicle control (DMSO) or 250 nM rotenone for 24 h was assessed by (C) MTT assay or (D) Crystal Violet assay. The viability of 
differentiated SH-SY5Y cells (10 µM ATRA and 1% FCS for 5 days) that were treated with (E) vehicle control (DMSO) or 250 nM 
rotenone or 250 nM rotenone with Lab4 or Lab4b CM or (F) pre-incubated with serum-free DMEM/F12 or 250 nM rotenone for 24 h 
was assessed by MTT assay. Data are expressed as percentage survival compared to the vehicle control that has been arbitrarily 
assigned as 100%. The data are presented as the mean ± standard error of the mean of at least three independent experiments. 
* P<0.05, ** P<0.01, *** P<0.001 or as stated vs the rotenone-treated cells or ### P<0.001 vs the vehicle control.
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patterns of change were observed with rotenone inducing a 
1.71-fold increase (P<0.001) that was reduced to 1.18-fold 
(P<0.001) and 0.92-fold (P<0.001) in the presence of Lab4 
and Lab4b CM, respectively. Reductions in apoptosis were 
significantly greater with Lab4b compared to Lab4 at both 
24 h (P<0.001, Figure 4A) and 48 h (P=0.001, Figure 4B).
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Figure 3. The effect of Lab4 and Lab4b CM on 1-methyl-4-phenylpyridinium iodide (MPP+)-induced toxicity in undifferentiated 
SH-SY5Y cells. The viability of undifferentiated SH-SY5Y cells that were treated with the vehicle control (water) or 2 µM MPP+ or 2 
µM MPP+ plus the stated concentration of Lab4 or Lab4b CM for 24 h was assessed by (A) MTT assay or (B) Crystal Violet assay. 
Data are expressed as percentage survival compared to the vehicle control that has been arbitrarily assigned as 100%. The data 
are presented as the mean ± standard error of the mean of at least five independent experiments. * P<0.05 vs the MPP+-treated 
cells or ### P<0.001 vs the vehicle control.
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Figure 4. The effect of Lab4 and Lab4b CM on rotenone-induced apoptosis and necrosis in undifferentiated SH-SY5Y cells. Levels 
of apoptosis (A+B) or necrosis (C+D) were assessed in undifferentiated SH-SY5Y cells that were treated with the vehicle control 
(DMSO) or 250 nM rotenone or 250 nM rotenone with Lab4 or Lab4b CM for 24 h (A+C) or 48 h (C+D). The data are presented as 
the mean ± standard error of the mean of relative luminescent units (RLU, A+B) or relative fluorescent units (RFU, C+D) from 
five independent experiments. * P<0.05, ** P<0.01 and *** P<0.001 vs rotenone-treated cells or ### P<0.001 vs the vehicle control.
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Apoptosis precedes secondary necrosis and at 24 h low 
levels of necrosis were detected (Figure 4C) with a trend 
towards increased levels of necrosis in rotenone-treated 
cells when compared to the control (1.64-fold, P=0.055, 
Figure 4C) that remained unchanged in the presence of 
Lab4 and Lab4b. Higher levels of necrosis were detected at 
48 h and rotenone exposure induced a significant increase 
compared to the control (2.52-fold, P<0.001, Figure 4D). 
In the presence of Lab4 or Lab4b necrosis rates were 1.97-
fold (P=0.006) and 1.60-fold (P<0.001), respectively, in line 
with the reduced apoptotic activity. Lab4b showed a trend 
towards increased capability compared to Lab4 (P=0.088, 
Figure 4D) similar to the effects observed during apoptosis.
Lab4 and Lab4b CM protect undifferentiated cells against 
ROS and induce genes involved in antioxidant defence
Exposure of undifferentiated SY-SY5Y cells to 10 µM 
rotenone for 6 h increased cellular ROS levels by 1.43-
fold (P<0.001) compared to the control and the degree of 
this effect was significantly reduced to 1.14-fold (P<0.001) 
in the presence of Lab4 CM and 1.23-fold (P=0.002) in the 
presence of Lab4b CM (Figure 5). No significant differences 
were observed between Lab4 and Lab4b. At rotenone 
concentrations between 250 nM and 10 µM, no increase 
in intracellular ROS levels was detected (Supplementary 
Figure S1B).
The expression of key genes involved in endogenous 
antioxidant defence in undifferentiated SH-SY5Y cells 
exposed to Lab4 and Lab4b for 24 h can be seen in Table 
1 and demonstrates a significant 1.51-fold (P=0.022) 
induction of glutathione reductase (GSR) expression with 
Lab4 and an 18.12-fold (P<0.001) induction in superoxide 
dismutase 2 (SOD2) expression in those treated with Lab4b. 
No changes in expression were observed for superoxide 
dismutase 1 (SOD1), glutathione peroxidase (GPx1) or 
catalase nor any differences between Lab4 and Lab4b for 
any gene.
4. Discussion
In an SH-SY5Y neuronal model, both Lab4 and Lab4b 
populations of microorganisms induced neuroprotective 
effects on challenged cells. Both consortia were found 
to possess antioxidant activity and were able to induce 
proliferation in SH-SY5Y cells. When either undifferentiated 
or retinoic acid-differentiated SH-SY5Y cells were 
challenged with the neurotoxin, rotenone, pre- or co-
exposure of the cells to Lab4 or Lab4b partly prevented 
rotenone-induced loss of viability. There were also 
protective effects against the development of apoptosis 
and necrosis and the intracellular accumulation of ROS.
Neurodegeneration occurs as a result of oxidative damage 
(Westfall et al., 2017) and there is a growing interest in the 
role of probiotic bacteria with the ability to impact upon 
the antioxidant capacity of the host (Wang et al., 2017). 
Improvements in oxidative status alongside improved 
behaviour have been observed in an Alzheimer’s disease 
mouse model supplemented with a multi-strain probiotic 
composed of strains of Bifidobacterium and Lactobacillus 
(Bonfili et al., 2017, 2018). Probiotics are thought to impart 
antioxidant effects by modulating endogenous antioxidant 
defence mechanisms and/or via the secretion of metabolites 
with antioxidant properties (Wang et al., 2017). Antioxidant 
activities were detected in both viable cells and conditioned 
media of Lab4 and Lab4b, albeit at differing levels, and 
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Figure 5. The effect of Lab4 and Lab4b CM on rotenone-induced 
cellular ROS accumulation in undifferentiated SH-SY5Y cells. 
Intracellular ROS levels in undifferentiated SH-SY5Y cells that 
were treated with the vehicle control (DMSO) or 10 µM rotenone 
or 10 µM rotenone with Lab4 or Lab4b CM for 6 h. Data are 
expressed as a percentage compared to the vehicle control that 
has been arbitrarily assigned as 100%. The data is presented 
as the mean ± standard error of the mean of four independent 
experiments. ** P<0.01, *** P<0.001 vs rotenone-treated cells 
or ### P<0.001 vs the vehicle control.
Table 1. Changes in gene expression of key antioxidant genes 
in undifferentiated SH-SY5Y cells exposed to CM from Lab4 
and Lab4b.1
Gene Lab4 Lab4b
Superoxide dismutase 1 1.19±0.40 0.85±0.21
Superoxide dismutase 2 1.41±0.15 18.12±5.75###
Glutathione peroxidase 1.06±0.15 0.80±0.12
Glutathione reductase 1.51±0.07# 1.18±0.08
Catalase 1.09±0.11 0.80±0.17
1 Gene expression is represented as a ratio in relation to an untreated 
control and is presented as the mean ± standard error of the mean 
of three independent experiments. # P<0.05 and ### P<0.001 vs the 
untreated control.
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highlighted both consortia as potential neuroprotective 
candidates.
Neurodegenerative disorders and age-related cognitive 
decline are associated with impaired neurogenesis; the 
process by which stem cells differentiate and proliferate into 
new neurones and other brain cells (Winner and Winkler, 
2015). In our study, Lab4 and Lab4b induced proliferation 
in both undifferentiated SH-SY5Y cells (Figure 1) and 
rotenone-challenged ATRA differentiated SH-SY5Y cells 
(Figures 2F). The multi-strain probiotic, VSL#3, has been 
shown to fully restore defective neurogenesis in antibiotic-
treated mice (Möhle et al., 2016) and a probiotic comprising 
Lactobacillus helveticus R0052 and Bifidobacterium 
longum R0175 supported mice exposed to chronic stress 
(Ait-Belgnaoui et al., 2014). Furthermore, other dietary 
antioxidants, such as the catechins found in green tea, have 
been shown to induce proliferation in undifferentiated 
SH-SY5Y cells and improve cognition in a murine model 
of brain aging (Pervin et al., 2017).
Neuronal cells are particularly vulnerable to oxidative 
damage (Lalkovičová and Danielisová, 2016) and both 
consortia possessed a comparable ability, as pre- and/or 
co-treatments, to attenuate losses in undifferentiated SH-
SY5Y cell viability in response to two well characterised 
neurotoxins and mediators of oxidative stress; rotenone 
and MPP+ (Giordano et al., 2012). The effects against 
rotenone are supported by the ability of both consortia 
to attenuate apoptosis and necrosis with Lab4b showing 
more activity than Lab4. These findings are consistent 
with an existing study showing the ability of glyceryl 
1,3-dipalmitate, purified from the fermentation products 
of Lactobacillus paracasei subsp. paracasei NTU 101, 
to protect undifferentiated SH-SY5Y cells from oxygen-
glucose deprivation and reperfusion-induced oxidative 
stress (Cheng and Pan, 2017). Metabolites induced by the 
intestinal commensal, Ruminococcus albus, have also been 
shown to protect undifferentiated cells from hydrogen 
peroxide, MPP+ and sodium arsenate-induced oxidative 
damage (Park et al., 2017).
Previous probiotic studies in the SH-SY5Y model have 
been performed on undifferentiated (naïve) cells (Cheng 
and Pan, 2017; Park et al., 2017) and in the current study 
we have shown that the neuroprotective effects of the Lab4 
and Lab4b consortia CM against the effects of rotenone, 
as pre- or co-incubations, are conserved in retinoic acid-
differentiated SH-SY5Y cells. Studies with differentiated 
SH-SY5Y cells are often favoured as these may represent 
a more relevant physiological format (Korecka et al., 2013; 
Lopes et al., 2010). It is worthy of note that Jantas et al. 
(2013) found that 10 µM rotenone had little impact on 
the viability of undifferentiated cells that had been pre-
exposed to reduced serum levels for 24 h whereas retinoic 
acid-differentiated cells were susceptible to rotenone under 
the same conditions (Jantas et al., 2013). This is in contrast 
to our study where the susceptibility of SH-SY5Y cells to 
rotenone was reduced upon retinoic acid-differentiation.
The mechanisms by which probiotic bacteria may impart 
neuroprotective effects have not been fully elucidated. 
Rotenone inhibits complex I of the mitochondrial electron 
transport chain leading to cellular ROS accumulation 
(Giordano et al., 2012) and our results indicate that Lab4 
and Lab4b possess comparable abilities to attenuate ROS 
accumulation in SH-SY5Y cells. Cellular ROS levels are 
controlled, in part, by glutathione reductase, an enzyme 
that maintains intracellular pools of reduced glutathione 
(Espinosa-Diez et al., 2015), and expression levels of the 
encoding gene (GSR) were found to be elevated in the 
presence of Lab4. Another enzyme, manganese-dependant 
superoxide dismutase (MnSOD), also contributes to 
intracellular ROS homeostasis by converting superoxide 
into oxygen and hydrogen peroxide (Espinosa-Diez et al., 
2015) and the expression of the encoding gene (SOD2) was 
induced in the presence of Lab4b. These data suggest the 
feasibility of different modes of action for Lab4 and Lab4b. 
These observations are supported by other studies showing 
reduced levels of ROS and increased levels of reduced 
glutathione and superoxide dismutase activity in the brains 
of Alzheimer’s disease model mice supplemented with the 
VSL#3 probiotic (Bonfili et al., 2018) and similar effects 
were seen with sodium arsenate-treated mice supplemented 
with Ruminococcus albus (Park et al., 2017). Future studies 
would investigate the ability of Lab4 and Lab4b CM to 
modulate the activity of complex I of the electron transport 
chain. 1-methylnicotinamde has been shown to impart 
neuroprotective effects by increasing complex I activity 
in rotenone-treated SH-SY5Y cells (Parsons et al., 2011).
Two potential limitations of our study involve firstly the 
duration of ATRA exposure used for the differentiation 
of SH-SY5Y cells. While there appears to be no consensus 
methodology for this process (Kovalevich and Langford, 
2013; Xicoy et al., 2017), Lopes et al. (2010) required 7 
days incubation to achieve a dopaminergic phenotype 
(Lopes et al., 2010) thus highlighting the possibility that 
5 days incubation may be insufficient to reach terminal 
differentiation. Secondly, the metabolite profiles for the 
Lab4 and Lab4b consortia have not been determined. 
In the study of O’Hagan et al. (2017) rats supplemented 
daily with the Lab4 consortium from weaning through to 
sacrifice (18 months) had increased brain levels of lactate, 
myo-inositol, γ-aminobutyric acid, fumarate, inosine and 
alanine (O’Hagan et al., 2017) for which there is reported 
evidence of antioxidant activity (Chen et al., 2013; Grosser 
et al., 2004; Groussard et al., 2000; Gudkov et al., 2006; Jiang 
et al., 2011; Lin et al., 2016). Lactate is a major metabolic 
end-product of lactobacilli (Klein et al., 1998) which is able 
to pass through the blood-brain barrier (Proia et al., 2016).
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In summary, this in vitro study indicates that the conditioned 
media from the Lab4 and Lab4b probiotic consortia may 
have potential neuroprotective properties as demonstrated 
by the observed ability to protect SH-SY5Y cells against 
the actions of rotenone with distinct mechanisms of action 
attributed to each consortium. This study provides a basis 
for future targeted in vivo studies comparing the efficacy 
of these potentially beneficial probiotic consortia.
Supplementary material
Supplementary material can be found online at https://doi.
org/10.3920/BM2018.0105.
Figure S1. The impact of rotenone on cell viability and 
intracellular ROS accumulation in undifferentiated SH-
SY5Y cells.
Figure S2. Lab4 and Lab4b exert a neuroprotective effect 
in rotenone-treated undifferentiated SH-SY5Y cells.
Figure S3. The impact of MPP+ on cell viability in 
undifferentiated SH-SY5Y cells.
Figure S4. Differentiation of SH-SY5Y cells with all-trans 
retinoic acid.
Table S1. Oligonucleotide primer sequences.
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